Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective

Area of Science:

• Biochemistry
• Molecular Biology
• Epigenetics

Background:

• Gene expression regulation involves DNA methylation, chromatin remodeling, and histone post-translational modifications.
• Histone acetylation/deacetylation by histone acetyltransferases (HATs) and histone deacetylases (HDACs) dynamically alters chromatin structure.
• Mammalian HDACs are classified into three families (I, II, III) based on sequence homology.

Purpose of the Study:

• To review the design, discovery, and development of synthetic modulators of histone deacetylases (HDACs).
• To discuss the in vitro/ex vivo activity and clinical potential of these novel HDAC inhibitors.
• To highlight challenges in HDAC inhibitor development, including toxicity and pharmacokinetic properties.

Main Methods:

• Review of current literature on synthetic HDAC modulators.
• Analysis of in vitro and ex vivo data regarding HDAC inhibitor activity.
• Evaluation of clinical trial data and preclinical studies for HDAC-targeted therapies.

Main Results:

• HDAC inhibitors induce histone hyperacetylation, impacting chromatin structure and gene expression.
• These inhibitors promote tumor cell growth arrest, differentiation, and apoptosis.
• HDAC inhibitors can potentiate the efficacy of DNA-targeting anticancer agents.

Conclusions:

• Synthetic HDAC modulators offer therapeutic potential in oncology.
• Overcoming non-specific toxicity and improving pharmacokinetic profiles are critical for clinical success.
• Further research into novel HDAC inhibitor design and application is warranted.